Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Other Accumulated Expenses of $841000.0 for Q1 2026, down 9.08% year-over-year from $925000.0 in Q1 2025, and down 10.91% quarter-over-quarter from $944000.0 in Q4 2025.
Powered by 
Analysis
Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Other Accumulated Expenses for 7 consecutive years, with $841000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 9.08% year-over-year to $841000.0; the TTM figure through Mar 2026 stood at $841000.0 (down 9.08% YoY), while the FY2025 annual figure was $944000.0, up 2.83% from the prior year.
- Other Accumulated Expenses fell to $841000.0 in Q1 2026 per JANX's latest filing, from $944000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.0 million in Q2 2023 and bottomed at $332000.0 in Q1 2022.
- Historically, Other Accumulated Expenses has averaged $699529.4 across 5 years, with a median of $718000.0 in 2024.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses soared 194.52% — and 2024, when it declined 29.75%.
- Janux Therapeutics' Other Accumulated Expenses stood at $623000.0 in 2022, then decreased by 11.88% to $549000.0 in 2023, then soared by 67.21% to $918000.0 in 2024, then climbed by 2.83% to $944000.0 in 2025, then retreated by 10.91% to $841000.0 in 2026.
- Business Quant data shows JANX's Other Accumulated Expenses at $841000.0 in Q1 2026, $944000.0 in Q4 2025, and $551000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 829,000.00 |
| Mar 31, 2026 | 841,000.00 |
| Dec 31, 2025 | 944,000.00 |
| Sep 30, 2025 | 551,000.00 |
| Jun 30, 2025 | 587,000.00 |
| Mar 31, 2025 | 925,000.00 |
| Dec 31, 2024 | 918,000.00 |
| Sep 30, 2024 | 778,000.00 |
| Jun 30, 2024 | 718,000.00 |
| Mar 31, 2024 | 805,000.00 |
| Dec 31, 2023 | 549,000.00 |
| Sep 30, 2023 | 609,000.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 734,000.00 |
| Dec 31, 2022 | 623,000.00 |
| Sep 30, 2022 | 609,000.00 |
| Jun 30, 2022 | 347,000.00 |
| Mar 31, 2022 | 332,000.00 |
| Dec 31, 2021 | 478,000.00 |
| Sep 30, 2021 | 517,000.00 |